… resistance suggesting that erlotinib sensitivity may be dependent … erlotinib treatment might
still be beneficial in a platinum pretreated patient population as no cross-resistance to erlotinib …

… cell culture models, where we showed that whereas the IC 50 of erlotinib sensitivity in untreated
versus cisplatin-treated cells … of erlotinib is substantially increased in the cisplatin-treated …

… On the basis of these findings, we did a randomised phase 3 trial to compare dacomitinib
with erlotinib in patients with advanced non-small-cell lung cancer, including patients with …

… in the erlotinib arm had squamous cell histology, and treatment was third line in 39.2% and
46.4% of patients, respectively. The primary study endpoint was time to tumor progression (…

… of tumor biology … cell lung cancer (NSCLC) treatment. Among these targets, epidermal growth
factor receptor (EGFR), or HER1, has received particular attention in lung cancer treatment. …

… therapy is being evaluated [11–13]. The present manuscript concerns the FDA's recent
approval of erlotinib as first-line maintenance treatment … SD) on first-line treatment with platinum-…

… lung cancer, it has been shown that the effect of treatment with the EGFR inhibitor erlotinib
is highest if the tumor cells … during erlotinib treatment from 23 patients with lung cancer in …

… (TKI) erlotinib has been at the forefront of changes in treatment practice for advanced non–small
cell lung cancer (NSCLC) over the past 10 years. Erlotinib was initially approved for use …

… Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung cancer (NSCLC)
has quite poor outcomes. We aimed to investigate whether adjuvant erlotinib therapy …

… A limitation of our study was that specific combinations of post-study therapy were not
documented, eg maintenance erlotinib plus chemotherapy; therefore, this limits the ability to fully …